Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Autor: Loriot Y; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr., Miller K; Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy., Fizazi K; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France., De Bono JS; Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK., Chowdhury S; Department of Urology, Guys and St Thomas' Hospital, London, UK., Higano CS; Department of Medicine, Division of Medical Oncology, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Noonberg S; Department of Early Clinical Development, Medivation, San Francisco, CA, USA., Holmstrom S; Health Economics and Outcomes Research, Astellas Pharma Europe, Leiden, Netherlands., Mansbach H; Department of Medical Affairs, Medivation, San Francisco, CA, USA., Perabo FG; Astellas Pharma Global Development, Northbrook, IL, USA., Phung D; Astellas Pharma Global Development, Northbrook, IL, USA., Ivanescu C; Consulting, Quintiles, Hoofddorp, Netherlands., Skaltsa K; Consulting, Quintiles, Barcelona, Spain; Department of Public Health, University of Barcelona, Barcelona, Spain., Beer TM; Division of Hematology and Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Tombal B; Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 May; Vol. 16 (5), pp. 509-21. Date of Electronic Publication: 2015 Apr 14.

[A critical assessment of phytotherapy for prostate cancer].

Autor: Perabo FG; Klinik und Poliklinik für Urologie, Universitätsklinikum, Sigmund-Freud-Strasse 25, 53105 Bonn. perabo@lycos.com, von Löw EC, Siener R, Ellinger J, Müller SC, Bastian PJ

Publikováno v: Der Urologe. Ausg. A [Urologe A] 2009 Mar; Vol. 48 (3), pp. 270-1, 274-83.

Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity.

Autor: Ellinger J; Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany. joerg.ellinger@ukb.uni-bonn.de, Bastian PJ, Ellinger N, Kahl P, Perabo FG, Büttner R, Müller SC, Ruecker Av

Publikováno v: Cancer letters [Cancer Lett] 2008 Jun 18; Vol. 264 (2), pp. 274-80. Date of Electronic Publication: 2008 Mar 10.

Soy isoflavone genistein in prevention and treatment of prostate cancer.

Autor: Perabo FG; Department of Urology, University Hospital, Bonn, Germany. perabo@lycos.com, Von Löw EC, Ellinger J, von Rücker A, Müller SC, Bastian PJ

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2008; Vol. 11 (1), pp. 6-12. Date of Electronic Publication: 2007 Oct 09.